These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23027683)

  • 21. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
    Molica S; Vitelli G; Levato D; Giannarelli D; Vacca A; Cuneo A; Ribatti D; Digiesi G
    Eur J Haematol; 2004 Jul; 73(1):36-42. PubMed ID: 15182336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
    Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
    Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
    Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
    Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
    Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
    J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia.
    Dickinson JD; Smith LM; Sanger WG; Zhou G; Townley P; Lynch JC; Pavletic ZS; Bierman PJ; Joshi SS
    Br J Haematol; 2005 Feb; 128(4):460-71. PubMed ID: 15686453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
    Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
    Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
    Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
    Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia.
    Tecchio C; Nichele I; Mosna F; Zampieri F; Leso A; Al-Khaffaf A; Veneri D; Andreini A; Pizzolo G; Ambrosetti A
    Eur J Haematol; 2011 Sep; 87(3):228-34. PubMed ID: 21595749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.
    Jain P; Keating M; Thompson PA; Trinh L; Wang X; Wierda W; Ferrajoli A; Burger J; Kantarjian H; Estrov Z; Abruzzo L; O'Brien S
    Am J Hematol; 2015 Jun; 90(6):471-7. PubMed ID: 25683856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada.
    Huang SJ; Gillan TL; Gerrie AS; Hrynchak M; Karsan A; Ramadan K; Smith AC; Toze CL; Bruyere H
    Genes Chromosomes Cancer; 2016 Jan; 55(1):16-24. PubMed ID: 26391112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis.
    Cuneo A; Rigolin GM; Bigoni R; De Angeli C; Veronese A; Cavazzini F; Bardi A; Roberti MG; Tammiso E; Agostini P; Ciccone M; Della Porta M; Tieghi A; Cavazzini L; Negrini M; Castoldi G
    Leukemia; 2004 Mar; 18(3):476-83. PubMed ID: 14712287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
    Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
    Cortes J; O'Brien S; Kantarjian H; Cork A; Stass S; Freireich EJ; Keating M; Pierce S; Estey E
    Leukemia; 1994 Dec; 8(12):2174-8. PubMed ID: 7808007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
    Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia.
    Karhu R; Tobin G; Thunberg U; Vilpo L; Sundström C; Knuutila S; Rosenquist R; Vilpo J
    Genes Chromosomes Cancer; 2003 Aug; 37(4):417-20. PubMed ID: 12800154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.